Brief: Annexon Presents Additional Positive Phase 3 Results For ANX005 CLQ

Annexon

25/06/2024 23:07

June 25 (Reuters) - Annexon Inc  ANNX.O :
    * ANNEXON PRESENTED ADDITIONAL POSITIVE PHASE 3 RESULTS FOR
ANX005
C1Q-TARGETED IMMUNOTHERAPY IN GUILLAIN-BARRÉ SYNDROME AT THE
2024 PNS ANNUAL MEETING
    * ANNEXON INC - SINGLE INFUSION OF ANX005 WAS GENERALLY
WELL-TOLERATED WITH SAFETY PROFILE SIMILAR TO PLACEBO
    * ANNEXON INC - DATA REINFORCE POTENTIAL OF ANX005 TO BE
FIRST
TARGETED IMMUNOTHERAPY TREATMENT FOR GBS
    * ANNEXON - ANX005-TREATED PATIENTS DEMONSTRATED FASTER,
MORE
COMPLETE RECOVERY FROM WEEK 1 THROUGH WEEK 26 ON PRIMARY,
MULTIPLE PRE-SPECIFIED ENDPOINTS

Source text for Eikon:  ID:nGNX7vhsz 
Further company coverage:  ANNX.O 

 ((reuters.briefs@thomsonreuters.com;))